Navigation Links
Early clinical data show galeterone safe, effective against prostate cancer
Date:3/31/2012

CHICAGO Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. Galeterone works against CRPC by blocking the androgen receptor, reducing levels of the ligand that binds to the receptor and degrading the androgen receptor protein.

"This drug has a novel combined mechanism of action," said co-lead researcher R. Bruce Montgomery, M.D., associate professor of medical oncology at the University of Washington School of Medicine in Seattle, Wash. "Cancer cells are sly and mutate to get around drugs. The fact that this drug hits the prostate cancer cell in three different ways may help prevent resistance. It is a well-tolerated drug that could potentially be more effective than drugs we have now."

In the ARMOR1 study, Montgomery and colleagues assigned 49 patients with CRPC to one of eight dose regimens in single or split oral escalation doses of 650 mg, 975 mg, 1,300 mg, 1,950 mg or 2,600 mg every day for 12 weeks. None of the patients had received chemotherapy for their prostate cancer.

Researchers reported that no patients reached a maximum tolerated dose. Most side effects were minor and included fatigue, nausea and diarrhea. Researchers observed transient, nonserious elevated liver function tests in 15 patients, many of whom were asymptomatic. Eleven of these patients temporarily stopped galeterone treatment, and six returned to treatment with no recurring liver function test elevations. One serious complication occurred involving rhabdomyolysis in the setting of simvastatin therapy and underlying renal insufficiency.

In early efficacy tests, 49 percent of patients had prostate-specific antigen (PSA) reductions of 30 percent or more; 11 of these patients had reductions of 50 percent or more. In addition, CT scans revealed reduction in tumor size for some patients.

"Because the androgen receptor controls PSA expression, improved PSA response shows that the drug is getting to the target," said Montgomery. "For the majority of patients, to reduce their PSAs by 30 percent or more is quite good in a phase I dose-finding trial."

Researchers will investigate long-term safety and an assessment of efficacy in a phase II study that Tokai Pharmaceuticals has planned for the second half of 2012.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007
2. Moms Lifestyle in Early Pregnancy Affects Babys Size
3. Early life stress may predict cardiovascular disease
4. MDS Announces Agreements to Divest MDS Pharma Services Early Stage Business
5. Alzheimers Association Applauds Social Security Administration for Adding Early-Onset Alzheimers to Its Compassionate Allowances Initiative
6. Alzheimers Foundation of America Applauds Social Security for Speeding Disability Benefits for Early-Onset Alzheimers Disease
7. JCI online early table of contents: Feb. 15, 2010
8. 29 Clear Channel stations Nationwide Raise Nearly $2.8 Million to Help Save the Lives of Kids Fighting Cancer and Other Deadly Diseases
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Early On, Hormone Therapy May Raise Womens Heart Risks
11. FriendsofWater.com Responds to the National Acadamy of Sciences Report that Millions of Americans Get Sick Yearly from Contaminated Water
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , ... May 24, 2016 , ... Mental health watchdog ... the Church of Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its ... “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening of the exhibit ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health (LLUH) has ... and expanded Children’s Hospital. Over 3,000 people looked on as the shovels hit the ... event photo slidehsow. , During the program, Richard H. Hart, MD, DrPH, president, ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... the perfect data logger for each job, ensuring the best suited solution to ... of MadgeTech data loggers at their lab in Istanbul. , Metroloji Okulu specializes ...
(Date:5/24/2016)... ... 2016 , ... Growing in popularity, more and more people continue to live ... easily accessible. Whether someone chooses to cut gluten out of their life for personal ... Grocery stocks their shelves with many different gluten-free products all year round. And they ...
(Date:5/24/2016)... ... May 24, 2016 , ... The number of health insurance ... 10% over last year, according to data in the forthcoming AIS’s Directory of ... stable, with a slight decrease in risk-based groups and a slight increase in ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016 ... , la première endoprothèse à double ... à l,intervention portant sur les membres inférieurs ... OrbusNeich, entreprise mondiale spécialisée dans la ... la vie, a élargi son portefeuille pour ...
(Date:5/24/2016)... -- Dutch surgeons have launched a ground-breaking medical app ... treat patients on a global scale. Medical professionals from ... and the US have already signed up for the ... a totally secure environment. Education  "Imagine a ... with a surgeon at Harvard to treat a bomb victim via ...
(Date:5/23/2016)... 23, 2016 According to ... Market by Product (Wheelchair, Scooters, Medical Beds, Bathroom ... Critical Care, Wound), Accessories (Lifting, Transfer) & by ... published by MarketsandMarkets, the patient handling equipment market ... 2021 at a CAGR of 10.5% during the ...
Breaking Medicine Technology: